A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Stopped early · Phase 1/Phase 2

Conditions studied: Prostate Cancer, Bone Metastases

In brief

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

Key facts

Study ID

NCT00757757

Run by

Novartis Pharmaceuticals

People needed

3

Starts

2008-09-01

Expected to finish

2009-08-01

Last updated by the study team

2020-12-19

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients with asymptomatic castrate-resistant prostate cancer with bone metastases who have not received any bisphosphonates in the 12 months prior to enrollment
• 18 years old and over

You may not qualify if…

• Plan to be on cytotoxic or biologic therapy during study
• Active dental problems
• Active heart complications
• Active infection
• Patients with moderate to severe swelling due to fluid
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• NV Cancer Institute — Las Vegas, Nevada, United States
• CTRC — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.